

Zoryve[®] (roflumilast) – New formulation approval

- On December 15, 2023, <u>Arcutis Biotherapeutics announced</u> the FDA approval of <u>Zoryve</u> (<u>roflumilast</u>), for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
- Another formulation of Zoryve, <u>roflumilast cream 0.3%</u>, is approved by the FDA for the topical treatment of plaque psoriasis in individuals 6 years of age and older.
- The efficacy of Zoryve was established in two randomized, double-blind, vehicle-controlled studies (STRATUM and Trial 203) in a total of 683 adult and pediatric patients with seborrheic dermatitis involving the scalp, face, and/or body. In each study, patients were randomized to receive Zoryve foam, 0.3%, or vehicle foam applied once daily for 8 weeks. The primary endpoint was the proportion of patients who achieved Investigator Global Assessment (IGA) treatment success at week 8. Success was defined as a score of "Clear" (0) or "Almost Clear" (1), plus a 2-grade improvement from baseline.
 - In STRATUM, 79.5% and 58.0% of patients achieved IGA success with Zoryve and vehicle foam, respectively (difference 20.6, 95% CI: 11.2, 30.0).
 - In Trial 203, 73.1% and 40.8% of patients achieved IGA success with Zoryve and vehicle foam, respectively (difference 33.8, 95% CI: 20.3, 47.4).
- Zoryve is contraindicated in patients with moderate to severe liver impairment.
- A warning and precaution for Zoryve is flammability.
- The most common adverse reactions (≥ 1%) with Zoryve use were nasopharyngitis, nausea, and headache.
- Zoryve should be applied as a thin layer once daily to affected areas on skin and/or scalp when they are not wet.
- Arcutis Biotherapeutics plans to launch Zoryve by the end of January 2024. Zoryve will be available as a 0.3% foam (3 mg of roflumilast per gram in 60-gram pressurized cans).



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.